Replies to post #92084 on Biotech Values

[DewDiligence]

AGN reacquires Botox cosmeceutical rights in Japan/China from GSK:

http://sec.gov/Archives/edgar/data/850693/000119312510053567/d8k.htm

GSK retains the Botox rights in these countries for medical indications. It never made sense to me that GSK, a company with zero presence in cosmeceuticals, was marketing Botox for cosmetic indications.

[DewDiligence]

FDA approves Botox for lower-limb spasticity:

http://finance.yahoo.com/news/u-fda-approves-botox-onabotulinumtoxina-130500712.html

Botox has been used off-label for this indication, but the FDA approval should help with reimbursement. Botox was FDA-approved for upper-limb spasticity in 2010 (#msg-47616915).